文献速递妇科

辅助化疗对I期子宫平滑肌肉瘤的预后影响

Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
PubMed 文献 · Gynecol Oncol · 2020-01-15

本研究基于美国国家癌症数据库2010-2014年接受子宫切除术的1059例I期子宫平滑肌肉瘤患者,采用倾向评分加权比较辅助化疗与无辅助化疗的生存差异。结果显示辅助化疗未改善总生存,低级别肿瘤患者接受辅助化疗反而生存更差。

要点

  • 辅助化疗未改善I期子宫平滑肌肉瘤患者的总生存。
  • 低级别肿瘤患者接受辅助化疗与更差生存相关。
  • 年龄、合并症评分、肿瘤大小、脉管浸润和分级为独立预后因素。

核心结论

  • 在I期子宫平滑肌肉瘤患者中,辅助化疗相比无辅助化疗未改善生存,且在低级别肿瘤患者中生存更差。

研究设计与样本

  • 观察性研究,纳入2010至2014年美国国家癌症数据库中接受子宫切除术的I期子宫平滑肌肉瘤患者1059例,其中514例接受辅助化疗,545例未接受。
  • 采用基于倾向评分的逆概率治疗加权平衡辅助化疗组与无辅助化疗组的临床特征,通过Cox模型估计风险比和95%置信区间。

主要发现

  • 辅助化疗组与无辅助化疗组的患者特征和肿瘤特征存在差异(P < .0001)。
  • 多因素生存分析显示患者年龄、合并症评分、肿瘤大小、脉管浸润和分级为独立预后因素。
  • 倾向评分加权后,辅助化疗组与无辅助化疗组的调整五年生存率分别为61.7%和61.3%,限制性平均生存时间分别为39.7个月和40.6个月。
  • 加权Cox分析中,辅助化疗组与无辅助化疗组的总生存死亡风险相似(HR = 1.08,95% CI = 0.85-1.37,P = .054)。
  • 亚组分析显示,低级别肿瘤患者接受辅助化疗相比无辅助化疗的五年生存率更差(82.3% vs. 91.5%),死亡风险增加(HR = 3.79,95% CI = 1.15-12.40,P = .028)。

临床怎么用

  • 对于I期子宫平滑肌肉瘤患者,辅助化疗不应常规推荐用于改善生存。
  • 低级别肿瘤患者应避免辅助化疗,因其与更差生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Determine the impact of adjuvant chemotherapy (ACT) and prognostic factors in surgically managed patients with stage I uterine leiomyosarcoma (ULMS). METHODS: Women who underwent hysterectomy and were diagnosed with stage I ULMS between 2010 and 2014 in the National Cancer Database were eligible for this observation study. Inverse probability of treatment weighting based on propensity score was used to balance clinical characteristics between ACT and no ACT patients. Hazard ratio (HR) and 95% confidence interval (CI) were estimated from Cox modeling. RESULTS: There were 1059 eligible patients with stage I ULMS including 514 treated with ACT and 545 with no ACT. Patient characteristics and tumor features varied in patients treated with ACT vs. no ACT (P < .0001). Multivariate survival analysis demonstrated that patient age, comorbidity score, tumor size, lymphovascular space invasion (LVSI) and grade were independent prognostic factors. After propensity score weighting to control for imbalance of prognostic clinical factors, adjusted five-year survival was 61.7% vs. 61.3% and restricted mean survival time was 39.7 vs. 40.6 months for ACT vs. no ACT, respectively. Risk of death in a weighted Cox analysis of overall survival was similar (HR = 1.08, 95% CI = 0.85-1.37, P = .054) for ACT vs. no ACT patients. Subset analysis demonstrated that survival was similar in ACT vs. no ACT patients categorized by age, tumor size and LVSI or with high grade or ungraded tumors. In contrast, patients with low grade tumors had worse 5-year survival (82.3% vs. 91.5%) and an increased risk of death (HR = 3.79, 95% CI = 1.15-12.40, P = .028) following ACT vs. no ACT. CONCLUSIONS: ACT did not improve survival over no ACT in patients with stage I ULMS and was inferior in patients with low grade tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vaz J, Tian C, Richardson MT, et al. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. Gynecol Oncol. 2020. PMID: 31954536. doi:10.1016/j.ygyno.2019.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。